Melis Nuray Anahtar, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lactobacillus | 3 | 2018 | 212 | 1.010 |
Why?
|
| Vagina | 3 | 2018 | 850 | 0.820 |
Why?
|
| Pneumocystis carinii | 1 | 2021 | 72 | 0.740 |
Why?
|
| Enterococcus faecium | 1 | 2021 | 101 | 0.720 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2021 | 49 | 0.700 |
Why?
|
| Listeriosis | 1 | 2021 | 147 | 0.700 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2021 | 242 | 0.690 |
Why?
|
| Laboratories, Hospital | 1 | 2021 | 192 | 0.670 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 246 | 0.650 |
Why?
|
| Brain Abscess | 1 | 2020 | 123 | 0.640 |
Why?
|
| Mucormycosis | 1 | 2020 | 102 | 0.640 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2021 | 342 | 0.630 |
Why?
|
| Cerebrospinal Fluid | 1 | 2021 | 540 | 0.590 |
Why?
|
| Graves Disease | 1 | 2019 | 239 | 0.580 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2019 | 273 | 0.550 |
Why?
|
| Vaginosis, Bacterial | 1 | 2018 | 154 | 0.520 |
Why?
|
| Cerebral Infarction | 1 | 2021 | 969 | 0.510 |
Why?
|
| Facial Paralysis | 1 | 2020 | 346 | 0.510 |
Why?
|
| Obstetric Labor Complications | 1 | 2018 | 244 | 0.500 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 530 | 0.490 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2016 | 1049 | 0.480 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 812 | 0.450 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 983 | 0.440 |
Why?
|
| Lung | 2 | 2021 | 10101 | 0.410 |
Why?
|
| Amyloidosis | 1 | 2020 | 877 | 0.400 |
Why?
|
| Metagenomics | 1 | 2016 | 474 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 7477 | 0.380 |
Why?
|
| Abdominal Pain | 3 | 2021 | 1070 | 0.340 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 1930 | 0.330 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2185 | 0.320 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 13013 | 0.310 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1469 | 0.270 |
Why?
|
| Kidney | 1 | 2020 | 7064 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 1063 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3670 | 0.220 |
Why?
|
| Phylogeny | 2 | 2021 | 2843 | 0.220 |
Why?
|
| Brain | 2 | 2021 | 27362 | 0.220 |
Why?
|
| Headache | 2 | 2021 | 1263 | 0.210 |
Why?
|
| Guanidines | 1 | 2023 | 194 | 0.210 |
Why?
|
| Elafin | 1 | 2022 | 30 | 0.210 |
Why?
|
| beta-Defensins | 1 | 2022 | 60 | 0.210 |
Why?
|
| Abortion, Missed | 1 | 2021 | 11 | 0.190 |
Why?
|
| Hepatomegaly | 1 | 2021 | 84 | 0.190 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2021 | 45 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2023 | 1967 | 0.190 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7951 | 0.190 |
Why?
|
| Splenomegaly | 1 | 2021 | 192 | 0.180 |
Why?
|
| Lethargy | 1 | 2021 | 43 | 0.180 |
Why?
|
| Anilides | 1 | 2023 | 413 | 0.180 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2021 | 234 | 0.170 |
Why?
|
| Dysarthria | 1 | 2020 | 56 | 0.170 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2020 | 37 | 0.170 |
Why?
|
| Anaplasmosis | 1 | 2020 | 37 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2020 | 100 | 0.170 |
Why?
|
| Acinetobacter Infections | 1 | 2020 | 73 | 0.170 |
Why?
|
| Fetal Death | 1 | 2021 | 434 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2021 | 327 | 0.160 |
Why?
|
| Heroin Dependence | 1 | 2020 | 173 | 0.160 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 161 | 0.160 |
Why?
|
| Acinetobacter baumannii | 1 | 2020 | 123 | 0.160 |
Why?
|
| Nausea | 1 | 2021 | 682 | 0.150 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 333 | 0.150 |
Why?
|
| Bacteria | 3 | 2023 | 2216 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 20762 | 0.140 |
Why?
|
| Genome, Viral | 1 | 2020 | 674 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 4648 | 0.130 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 541 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 178 | 0.130 |
Why?
|
| Vomiting | 1 | 2019 | 655 | 0.130 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2017 | 294 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2023 | 1068 | 0.130 |
Why?
|
| South Africa | 3 | 2017 | 1873 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 827 | 0.120 |
Why?
|
| Abdomen | 1 | 2021 | 1136 | 0.120 |
Why?
|
| Kidney Calculi | 1 | 2019 | 458 | 0.120 |
Why?
|
| Methotrexate | 1 | 2021 | 1721 | 0.120 |
Why?
|
| Sequence Analysis | 1 | 2015 | 240 | 0.120 |
Why?
|
| Contraceptive Agents, Female | 1 | 2015 | 123 | 0.120 |
Why?
|
| Humans | 28 | 2023 | 768171 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2021 | 1321 | 0.110 |
Why?
|
| Probiotics | 1 | 2018 | 387 | 0.110 |
Why?
|
| Progestins | 1 | 2015 | 302 | 0.110 |
Why?
|
| Fever | 1 | 2021 | 1614 | 0.110 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 533 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2021 | 2874 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2017 | 577 | 0.100 |
Why?
|
| Africa | 1 | 2015 | 725 | 0.100 |
Why?
|
| Dyspnea | 1 | 2021 | 1352 | 0.100 |
Why?
|
| Immunization | 1 | 2017 | 1219 | 0.100 |
Why?
|
| AIDS Vaccines | 1 | 2019 | 900 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 3214 | 0.100 |
Why?
|
| Biodiversity | 1 | 2015 | 345 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2167 | 0.100 |
Why?
|
| Placenta | 1 | 2021 | 1725 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2017 | 711 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2023 | 4213 | 0.090 |
Why?
|
| HIV-1 | 3 | 2019 | 6963 | 0.090 |
Why?
|
| Cross Infection | 1 | 2020 | 1425 | 0.090 |
Why?
|
| Radiography | 1 | 2021 | 6986 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 1481 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 2204 | 0.090 |
Why?
|
| Feces | 1 | 2016 | 1511 | 0.080 |
Why?
|
| Silicon | 1 | 2009 | 143 | 0.080 |
Why?
|
| Female | 12 | 2022 | 397187 | 0.080 |
Why?
|
| Pregnancy | 2 | 2021 | 30255 | 0.070 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 594 | 0.070 |
Why?
|
| HIV Infections | 4 | 2017 | 17569 | 0.070 |
Why?
|
| Titanium | 1 | 2009 | 495 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2020 | 6004 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2666 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 36741 | 0.070 |
Why?
|
| Cadherins | 1 | 2011 | 905 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2019 | 6412 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 2237 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 4786 | 0.060 |
Why?
|
| Cytokines | 2 | 2021 | 7452 | 0.060 |
Why?
|
| Nanostructures | 1 | 2009 | 553 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15453 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 223646 | 0.060 |
Why?
|
| Liver | 1 | 2019 | 7578 | 0.050 |
Why?
|
| Hydrazones | 1 | 2023 | 105 | 0.050 |
Why?
|
| Boston | 3 | 2020 | 9374 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 6395 | 0.050 |
Why?
|
| Interleukin-16 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20225 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 4423 | 0.050 |
Why?
|
| Hemolysis | 1 | 2004 | 417 | 0.050 |
Why?
|
| Muramidase | 1 | 2022 | 163 | 0.050 |
Why?
|
| Interleukin-1alpha | 1 | 2022 | 88 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2022 | 100 | 0.050 |
Why?
|
| Inflammation | 1 | 2021 | 10873 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2011 | 2857 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2021 | 6873 | 0.050 |
Why?
|
| Disease Outbreaks | 2 | 2020 | 1761 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.040 |
Why?
|
| Burn Units | 1 | 2020 | 143 | 0.040 |
Why?
|
| Microfluidics | 1 | 2004 | 672 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2022 | 855 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2009 | 2880 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 406 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2022 | 546 | 0.040 |
Why?
|
| Carbapenems | 1 | 2020 | 125 | 0.040 |
Why?
|
| Interferons | 1 | 2022 | 720 | 0.040 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 215 | 0.040 |
Why?
|
| Progesterone | 1 | 2022 | 752 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 340 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2019 | 330 | 0.040 |
Why?
|
| Injections, Jet | 1 | 2017 | 8 | 0.040 |
Why?
|
| Virus Replication | 2 | 2019 | 2458 | 0.040 |
Why?
|
| Interleukins | 1 | 2022 | 796 | 0.040 |
Why?
|
| Injections, Intradermal | 1 | 2017 | 117 | 0.040 |
Why?
|
| Chemokines | 1 | 2021 | 963 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 704 | 0.030 |
Why?
|
| Prevotella | 1 | 2017 | 81 | 0.030 |
Why?
|
| Bacteria, Anaerobic | 1 | 2017 | 71 | 0.030 |
Why?
|
| Contrast Media | 1 | 2009 | 5330 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 472 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2019 | 1162 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2023 | 1430 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 687 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 591 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14729 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2004 | 2418 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 1035 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2023 | 1398 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 3814 | 0.030 |
Why?
|
| Needles | 1 | 2017 | 461 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2017 | 5902 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1596 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2722 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 841 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1361 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3229 | 0.030 |
Why?
|
| Contraception | 1 | 2015 | 362 | 0.020 |
Why?
|
| Micromanipulation | 1 | 2012 | 53 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2023 | 81760 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 60066 | 0.020 |
Why?
|
| Algorithms | 2 | 2023 | 14164 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 223487 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 89169 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4505 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2785 | 0.020 |
Why?
|
| Proteome | 1 | 2019 | 1890 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 520 | 0.020 |
Why?
|
| Animals | 5 | 2023 | 169285 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2009 | 540 | 0.020 |
Why?
|
| Mice | 3 | 2023 | 82049 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 6231 | 0.020 |
Why?
|
| Alleles | 1 | 2019 | 6894 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 171502 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 445 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 2009 | 1435 | 0.020 |
Why?
|
| Nanomedicine | 1 | 2009 | 292 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3886 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 1166 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 2474 | 0.020 |
Why?
|
| Male | 3 | 2020 | 364731 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2012 | 1334 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2012 | 4168 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3800 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2012 | 714 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 873 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 1651 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 2527 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 1728 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1613 | 0.010 |
Why?
|
| HIV | 1 | 2012 | 1597 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 1418 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 18349 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4415 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9613 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22290 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2012 | 3161 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2017 | 41753 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 54924 | 0.010 |
Why?
|
| Colon | 1 | 2011 | 1801 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2004 | 1163 | 0.010 |
Why?
|
| Diffusion | 1 | 2004 | 815 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12543 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10840 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 5505 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21538 | 0.010 |
Why?
|
| Genotype | 1 | 2012 | 13045 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11095 | 0.010 |
Why?
|
| Mutation | 1 | 2019 | 30237 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 10266 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 23782 | 0.000 |
Why?
|